Horizon Pharma Inc. recorded an $11.6 million loss in the second quarter, its last quarter before the completion of an initial public offering of stock last month.
Dr. Reddy's Laboratories Ltd. said on Aug. 31 that it settled a lawsuit brought by Pfizer Inc. over a generic version of Pfizer's cholesterol drug Lipitor.
Keryx Biopharmaceuticals Inc. said on Aug. 31 that an independent monitoring board recommended that its late-stage study of a potential colorectal cancer treatment can continue as planned until it is completed.
University of California, Davis researchers developed a computer model to test the effects of medications for arrhythmia, or abnormal heart rhythm, before they are used in patients.
Life Technologies is now offering Protein Thermal Shift complete solution, an application for Applied Biosystems real-time PCR systems that enables analysis of protein thermal stability.
Special Optics offers objective lens solutions optimized for use in two-photon microscopy systems. These apochromatic objectives are customized with high numerical apertures and long working distances for use with various sample sizes and applications.
Lumora Ltd and 3M have signed a joint development and licensing agreement. Conclusion The agreement allows 3M to develop and sell nucleic acid test kits utilising Lumora’s BART technology.
Researchers have created and tested miniature devices that are implanted in tumors to generate oxygen, boosting the killing power of radiation and chemotherapy.
Critical Outcome Technologies Inc. announced recent experiments demonstrating clear evidence of COTI-2's ability to significantly inhibit the growth of cancer cells that over express Akt/Akt2, confirming it as a promising targeted therapy candidate.
Daiichi Sankyo Company submitted a supplemental New Drug Application for an additional indication of Diagnogreen 25 mg intravenous injection for near-infrared fluorescence angiography during cerebrovascular surgery.
Canadian drugmaker Valeant Pharmaceuticals International Inc. said it will buy cold remedy maker Afexa Life Sciences Inc. for about $77.6 million.
A Caris & Co. analyst upgraded the stock of drug developer Alkermes Inc., pointing to the company's pending acquisition of a drug technology business.
A new lupus treatment developed by Human Genome Sciences Inc. is receiving a lukewarm reception from doctors so far, with demand for the drug shaping up to be much softer than expected, according to a Citi analyst.
The National Institutes of Health, in partnership with the Department of Defense, is building a central database on traumatic brain injuries.